Tuesday, December 15, 2009

Chelsea Therapeutics Granted Approval to Change the Primary Endpoint and Increase Enrollment in Droxidopa Pivot.. http://bit.ly/79ltVP
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)